TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22997217

Group type: EXPERIMENTAL
Intervention: Water-based exercise training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Land-based exercise training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 53
Study: 20718396

Group type: EXPERIMENTAL
Intervention: Education program for clinicians to support patients making decisions about place of end-of-life care
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 88
Study: 18788218

Group type: EXPERIMENTAL
Intervention: Synergy (minimal extracorporeal circulation system)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard CPB
Number of subjects: 20
Study: 16827017

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: calcium hydroxide liner (Life)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: cavity varnish (Copalite)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: resin modified glass ionomer liner (Vitrebond)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: dentin adhesive resin liner (Single Bond)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: chlorhexidine disinfectant (Consepsis)
Number of subjects: 120
Study: 12926581

Group type: EXPERIMENTAL
Intervention: Health Utility Index (HUI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Standard Gamble (SG)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rating scales
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Traditional health status measures (CHAQ, ASK)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Parental ratings
Number of subjects: 80
Study: 10997806

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 plus carboplatin 6 AUC (group A)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Paclitaxel 225 mg/m2 plus carboplatin 6 AUC (group B)
Number of subjects: 198
Study: 9144347

Group type: EXPERIMENTAL
Intervention: TIB, tibolone, 2.5 mg/day continuously, orally
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: PO, peroral E2, 2 mg/day continuously, plus sequential oral dydrogesterone (DYD), 10 mg/day, for 14 days of a 28-day cycle
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: TTS, transdermal E2 by patch releasing 50 microg/day, plus DYD as above
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 140
Study: 1388338

Group type: EXPERIMENTAL
Intervention: Ketorolac (60 mg)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Dezocine (6 mg)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Fentanyl (100 micrograms, control group)
Number of subjects: 136
Study: 3979761

Group type: EXPERIMENTAL
Intervention: Ensure diet preparation for 48 hours
Number of subjects: 72

Group type: COMPARATOR
Intervention: Clear liquid diet preparation for 48 hours
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ensure with two consecutive evenings of laxatives without enemas
Number of subjects: 72

Group type: COMPARATOR
Intervention: Clear liquid diet with evening-laxative and morning-enema regimen
Number of subjects: 72
Study: 29661229

Group type: EXPERIMENTAL
Intervention: 125 mm Exeter V40 stem
Number of subjects: 220

Group type: COMPARATOR
Intervention: 150 mm Exeter V40 stem
Number of subjects: 220
Study: 28668422

Group type: EXPERIMENTAL
Intervention: Model-based iterative reconstruction (MBIR)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Adaptive statistical iterative reconstruction (ASIR)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Filtered back projection (FBP)
Number of subjects: 89
Study: 25523287

Group type: EXPERIMENTAL
Intervention: MK-0888 (VEGFR-2 inhibitor) at doses up to 100 mg in healthy volunteers; pharmacokinetics and safety evaluated.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MK-0888 (VEGFR-2 inhibitor) at doses of 6-100 mg administered up to twice daily in cancer patients; pharmacokinetics and safety evaluated.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MK-0888 (VEGFR-2 inhibitor) at doses of 50 mg twice daily and higher for multiple-dose administration.
Number of subjects: 0
Study: 23688651

Group type: EXPERIMENTAL
Intervention: Nonpurpuragenic 595-nm pulsed dye laser (PDL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Microsecond 1064-nm neodymium:yttrium-aluminum-garnet (Nd:YAG) laser
Number of subjects: 14
Study: 21367884

Group type: EXPERIMENTAL
Intervention: Germinated barley foodstuff (GBF), 30 g daily for two months along with standard drug therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Germinated barley foodstuff (GBF)
Number of subjects: 41
Study: 18510613

Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient (ADC) measurement in cirrhotic patients with minimal hepatic encephalopathy (HE)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: ADC values of white matter regions (frontal and parietal)
Number of subjects: 64

Group type: COMPARATOR
Intervention: ADC measurement
Number of subjects: 64
Study: 16781224

Group type: EXPERIMENTAL
Intervention: Stenting with abciximab
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty with abciximab
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Early reperfusion (<3 hours)
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Early reperfusion in high-risk patients (<3 hours)
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Early reperfusion in low-risk patients (<3 hours)
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Door-to-balloon times in patients presenting early (<2 hours)
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Door-to-balloon times in patients presenting late (>2 hours)
Number of subjects: 2082
Study: 14604201

Group type: EXPERIMENTAL
Intervention: 1.36% glucose/7.5% icodextrin
Number of subjects: 11

Group type: COMPARATOR
Intervention: 1.36% glucose
Number of subjects: 11

Group type: COMPARATOR
Intervention: 7.5% icodextrin
Number of subjects: 11

Group type: COMPARATOR
Intervention: 3.86% glucose
Number of subjects: 11
Study: 11095449

Group type: EXPERIMENTAL
Intervention: Micronized estradiol (E2) 1 or 2 mg daily for 3 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Micronized estradiol (E2)
Number of subjects: 59
Study: 9347428

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.49 microgram/kg/min)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Alfentanil (1.99 micrograms/kg/min)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Remifentanil (0.25 microgram/kg/min)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 35

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 35
Study: 8180725

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HD)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Drug treatment (DT)
Number of subjects: 54
Study: 3529151

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 30808230

Group type: EXPERIMENTAL
Intervention: Utidelone plus capecitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 0
Study: 28233343

Group type: EXPERIMENTAL
Intervention: Computerized brain fitness exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory support system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment groups (Computerized brain fitness exercise and Memory support system)
Number of subjects: 0
Study: 25909969

Group type: EXPERIMENTAL
Intervention: Rule of threes algorithm with oxytocin 3 IU
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous infusion of oxytocin (30 IU in 0.9% normal saline/500 ml)
Number of subjects: 60
Study: 24263699

Group type: EXPERIMENTAL
Intervention: Clinic visits
Number of subjects: 175

Group type: COMPARATOR
Intervention: Home lighting
Number of subjects: 175
Study: 20372949

Group type: EXPERIMENTAL
Intervention: Topical fluoride application (sodium fluoride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical enamel treatment with acidulated phosphate fluoride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acidulate fluoride-free solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Professional brushing, ultrasound action, or chemical extraction
Number of subjects: 0
Study: 19590159

Group type: EXPERIMENTAL
Intervention: Cardiovascular endurance training (CVE) for 10 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Balance and flexibility training (FLEX) for 10 months
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both CVE and FLEX
Number of subjects: 55
Study: 17996126

Group type: EXPERIMENTAL
Intervention: 5% CO2
Number of subjects: 10

Group type: COMPARATOR
Intervention: RA
Number of subjects: 10
Study: 15102146

Group type: EXPERIMENTAL
Intervention: Anticipated regret when 'nearly won' vs 'clearly lost' a contest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipated regret and self-blame when 'nearly caught' vs 'clearly missed' a train
Number of subjects: 0
Study: 11238542

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9574640

Group type: EXPERIMENTAL
Intervention: 5% albumin solution (hypervolemia group, n = 19)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal saline solution + 5% albumin solution (normovolemia group, n = 24)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 5% albumin solution (hypervolemia group)
Number of subjects: 43
Study: 8160445

Group type: EXPERIMENTAL
Intervention: Monovaccines
Number of subjects: 3663

Group type: EXPERIMENTAL
Intervention: Trivaccine
Number of subjects: 3663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3663
Study: 2971597

Group type: EXPERIMENTAL
Intervention: CAF plus Provera 200 mg daily for 3 weeks followed cyclically by Tamoxifen 20 mg daily for 3 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, adriamycin, 5‐fluorouracil)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Adjuvant cyclical hormonal therapy
Number of subjects: 46
Study: 31869312

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 30
Study: 30077810

Group type: EXPERIMENTAL
Intervention: Olodaterol (5 or 10 μg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formoterol (12 μg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28550756

Group type: EXPERIMENTAL
Intervention: ICM plus telehealth monitoring
Number of subjects: 51

Group type: COMPARATOR
Intervention: ICM
Number of subjects: 51
Study: 26194648

Group type: EXPERIMENTAL
Intervention: Universal coverage of insecticide-treated nets (ITNs) only
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Universal coverage of insecticide-treated nets (ITNs) combined with high coverage of indoor residual spraying (IRS)
Number of subjects: 300
Study: 23183220

Group type: EXPERIMENTAL
Intervention: Right PPC cTBS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left DLPFC cTBS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right DLPFC cTBS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham cTBS
Number of subjects: 0
Study: 21971726

Group type: EXPERIMENTAL
Intervention: Strengthening exercises of the lower extremities at 70% of 1RM, three times/week for ten weeks
Number of subjects: 32
Study: 18477161

Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment for 4-6 months until a cumulative dose of 120 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study: 16546214

Group type: EXPERIMENTAL
Intervention: 2 g acamprosate
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: 3 g acamprosate
Number of subjects: 601

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: 2 g acamprosate (post-hoc analysis)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: 3 g acamprosate (post-hoc analysis)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Placebo (post-hoc analysis)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: 2 g acamprosate (subgroup analysis)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: 3 g acamprosate (subgroup analysis)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Placebo (subgroup analysis)
Number of subjects: 601
Study: 14629775

Group type: EXPERIMENTAL
Intervention: Participative Ergonomics protocol performed by an ergonomist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graded Activity based on cognitive behavioural principles by a physiotherapist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care provided by an occupational physician according to Dutch guidelines
Number of subjects: 0
Study: 12271193

Group type: EXPERIMENTAL
Intervention: Huntleigh Nimbus 3
Number of subjects: 141

Group type: COMPARATOR
Intervention: Aura Cushion
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Pegasus Cairwave Therapy System
Number of subjects: 141

Group type: COMPARATOR
Intervention: ProActive Seating Cushion
Number of subjects: 141
Study: 9011895

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron during cardiopulmonary bypass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 20
Study: 1307904

Group type: EXPERIMENTAL
Intervention: T-Bar (n = 21)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (n = 22)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation (n = 19)
Number of subjects: 62
Study: 6094655

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional antiulcer agents (Control)
Number of subjects: 48
Study: 31492797

Group type: EXPERIMENTAL
Intervention: GRACE risk score and associated treatment recommendations
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3000
Study: 30005312

Group type: EXPERIMENTAL
Intervention: Worksite Heart Health Improvement Project (WHHIP)
Number of subjects: 98
Study: 26717958

Group type: EXPERIMENTAL
Intervention: Parent health behavior changes and feeding practices
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Greater parental monitoring
Number of subjects: 590
Study: 23306715

Group type: EXPERIMENTAL
Intervention: Steroid group (ropivacaine, dexamethasone, isepamicin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (ropivacaine, isepamicin)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Steroid group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 20523113

Group type: EXPERIMENTAL
Intervention: HB‐AS02 vaccine (0 and 1 month)
Number of subjects: 450
Study: 16322166

Group type: EXPERIMENTAL
Intervention: Lactation consultant intervention (2 prenatal meetings, postpartum hospital visit, home visits, and telephone calls)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 304
Study: 11748388

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: M6G
Number of subjects: 8
Study: 9504193

Group type: EXPERIMENTAL
Intervention: Lysine Clonixinate (LC) 125 mg
Number of subjects: 131

Group type: COMPARATOR
Intervention: Paracetamol 500 mg + Codeine 30 mg
Number of subjects: 131
Study: 8306757

Group type: EXPERIMENTAL
Intervention: 22-mg transdermal nicotine therapy with group counseling for 8 weeks (study 1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 22-mg transdermal nicotine therapy for 4 weeks followed by 11-mg for 2 weeks with brief individual counseling (study 2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 3179052

Group type: EXPERIMENTAL
Intervention: Viscoelastic fluid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium hyaluronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxypropylmethylcellulose (HPMC)
Number of subjects: 0
Study: 12858225

Group type: EXPERIMENTAL
Intervention: 1% climbazole
Number of subjects: 10
Study: 29847967

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (1 μg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intranasal saline, intravenous saline and propofol (group P)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intranasal saline, intravenous sulfentanil and propofol (group SP)
Number of subjects: 90
Study: 26081140

Group type: EXPERIMENTAL
Intervention: Ginsenoside Rd
Number of subjects: 589
Study: 25519844

Group type: EXPERIMENTAL
Intervention: Individually tailored biopsychosocial intervention for 10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care for 10 weeks
Number of subjects: 0
Study: 22314873

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (n=28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Expectant management (n=27)
Number of subjects: 55
Study: 20579522

Group type: EXPERIMENTAL
Intervention: Satiereal (176.5 mg extract per day, n = 31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 60
Study: 18566196

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg po (Group G)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 51
Study: 15898938

Group type: EXPERIMENTAL
Intervention: DBX paste
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DBX putty
Number of subjects: 60

Group type: COMPARATOR
Intervention: DFDBA (control)
Number of subjects: 60
Study: 12757969

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) 150 mg/day
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: DMI + CM
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo + Non-contingent voucher control
Number of subjects: 160
Study: 10680303

Group type: EXPERIMENTAL
Intervention: Esmolol (500 micrograms/kg loading dose followed by 100 micrograms/kg/h infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diltiazem (0.15 mg/kg loading dose followed by 5 mg/h infusion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 60
Study: 8768490

Group type: EXPERIMENTAL
Intervention: Training interventions aimed at supporting perceptual and pattern-recognition activities in dynamic environments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 1817959

Group type: EXPERIMENTAL
Intervention: Lamotrigine (100, 200, and 300 mg/day, b.i.d. regimen)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7104913

Group type: EXPERIMENTAL
Intervention: Intranasally administered phenylephrine (doses from 0.5 to 4 mg, total 7.5 to 15 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo of identical appearance
Number of subjects: 26
Study: 31122926

Group type: EXPERIMENTAL
Intervention: Educational attainment (each additional standard deviation of education, 3.6 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking behaviour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined risk factors (BMI, systolic blood pressure, smoking behaviour)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational attainment
Number of subjects: 0
Study: 29510699

Group type: EXPERIMENTAL
Intervention: Physically active academic lessons (2 x 45 minutes weekly for 10 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Physically active academic lessons
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Facilitators for implementation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Barriers for implementation
Number of subjects: 30
Study: 26933094

Group type: EXPERIMENTAL
Intervention: Oral opioid treatment
Number of subjects: 31
Study: 24916953

Group type: EXPERIMENTAL
Intervention: Prehospital decision system allowing ambulance nurses to transport older adults directly to geriatric care at a community‐based hospital (CH)
Number of subjects: 806

Group type: COMPARATOR
Intervention: Control group transported to the emergency department (ED)
Number of subjects: 806
Study: 23190932

Group type: EXPERIMENTAL
Intervention: Functional exercise class (twice weekly for six weeks from week 12 to week 18 post surgery) supervised by a chartered Physiotherapist
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 70
Study: 20709000

Group type: EXPERIMENTAL
Intervention: Intradermal TIV (15 μg HA per strain)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional TIV (15 μg HA per strain)
Number of subjects: 62
Study: 16903003

Group type: EXPERIMENTAL
Intervention: Stratified multivariate Cox regression model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survival time approach for analyzing AEs
Number of subjects: 0
Study: 16382423

Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive-behavior therapy (IT condition)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed treatment (DT condition)
Number of subjects: 40
Study: 11916777

Group type: EXPERIMENTAL
Intervention: PFC (perflubron emulsion)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 9
Study: 9857664

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7611746

Group type: EXPERIMENTAL
Intervention: 2.5 ppm capsaicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5.0 ppm capsaicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: vehicle food
Number of subjects: 0

Group type: COMPARATOR
Intervention: non-chilli flavoured food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5.0 ppm capsaicin in tomato juice vehicle
Number of subjects: 0
Study: 2375815

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (Rehydralyte) containing 75 mEq/L of Na
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous fluids (Ringer's Lactate and a solution of 56 mEq/L of Na)
Number of subjects: 0
Study: 199129

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate and oral fluphenazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0